Flexion Therapeutics Announces Positive Topline Results From Phase 2a Pharmacokinetic Trial With Lead Compound FX006

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BURLINGTON, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced positive topline clinical trial results from a Phase 2a synovial fluid PK study of FX006, which demonstrated, for the first time, that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks. FX006 is Flexion's novel, non-opioid, sustained-release, IA formulation of TCA. It is designed to provide prolonged pain relief for the treatment of osteoarthritis (OA) of the knee, while potentially avoiding untoward systemic effects associated with immediate-release steroids.

Help employers find you! Check out all the jobs and post your resume.

Back to news